micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr
Drug approach to treatment for obesity in adults: perspectives and considerations

Drug approach to treatment for obesity in adults: perspectives and considerations

Source : https://pubmed.ncbi.nlm.nih.gov/38345504/

Obesity is considered a chronic disease and a serious public-health issue in Spain, as well as in many other countries, primarily because of it being a significant risk factor for...

Obesity is a chronic disease and major public health issue in Spain, significantly increasing risk for multiple chronic conditions and cancers, with weight loss improving health outcomes.

Profile Image
  • Saved

1yr
Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic

Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic

Source : https://pubmed.ncbi.nlm.nih.gov/38566891/

The "new epidemic," as WHO calls obesity, is caused by overeating, which, having exceeded the body's actual needs, accumulates in the form of health-damaging fat deposits. Moving more and eating...

The article examines obesity, its causes, compulsive forms like food addiction, and explores pharmacological treatments, including a new anorectic, for managing compulsive obesity.

Profile Image
  • Saved

1yr
Major Advances in Diabetes Research and Treatment Unveiled at ADA Scientific Sessions

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, highlights key themes from this year’s ADA Scientific Sessions, including significant progress in obesity treatment, type 1 diabetes, technology, health disparities, and innovation. Notable studies, such as the FLOW trial on GLP-1 receptor agonists for kidney outcomes and the Surmount OSA study on sleep apnea, were discussed.

Dr. John Buse shared insights from the Catalyst Study, revealing a high prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, potentially reshaping future screening and treatment guidelines.

Profile Image
  • 1yr
    Fascinating studies and gives us another armament to control DM, HTN ASVD , CKD hopefully in the near future thanks
  • Saved

1yr
Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options

Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options

Source : https://pubmed.ncbi.nlm.nih.gov/38156451/

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through...

Obesity drives atrial fibrillation through multiple mechanisms, worsening outcomes and impacting treatment efficacy. Weight loss improves AF risk and recurrence, highlighting the need for personalized management strategies.

Profile Image
  • Saved

1yr
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38078870/

ClinicalTrials.gov Identifier: NCT04660643.

Continued tirzepatide treatment effectively maintains and enhances initial weight loss in individuals with obesity, while withdrawal leads to significant weight regain.

Profile Image